Acrivon Therapeutics, Inc.
ACRV
$2.06
-$0.04-1.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.65% | 7.74% | 3.29% | -6.20% | -24.57% |
| Total Depreciation and Amortization | 24.83% | 30.65% | 34.79% | 52.35% | 63.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.88% | 17.43% | 33.79% | 35.71% | 22.85% |
| Change in Net Operating Assets | -713.37% | -227.86% | -199.51% | -104.72% | -88.34% |
| Cash from Operations | 11.17% | 5.07% | 3.05% | -8.43% | -33.24% |
| Capital Expenditure | 48.50% | 19.19% | 39.70% | 26.36% | -12.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.61% | 269.35% | 238.30% | 243.97% | 223.12% |
| Cash from Investing | -19.65% | 256.26% | 227.68% | 229.23% | 214.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 730,600.00% | -100.00% | -100.00% | -100.00% | -100.00% |
| Repurchase of Common Stock | 83.54% | 83.73% | 70.24% | 61.99% | -15.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.70% | -- | -- | -100.00% | -100.58% |
| Cash from Financing | 367.35% | -100.36% | -100.62% | -101.01% | -102.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.82% | -135.55% | -53.00% | -160.00% | -154.51% |